Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Treatment of Idiopathic Pulmonary Fibrosis Patients With HB0056
NCT07909655 is registered in ClinicalTrials.gov with Shanghai Huaota Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Treatment of Idiopathic Pulmonary Fibrosis Patients With HB0056
- Lead sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- December 31, 2028
- Enrollment
- 75 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
idiopathic pulmonary fibrosis (ipf)
Arms
As registered; 3 arms.
-
HB0056 group 1
-
HB0056 group 2
-
control group
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Change from Baseline in FVC% (Percent of Predicted FVC value) to week 24
Lead sponsor's other trials
Shanghai Huaota Biopharmaceutical Co., Ltd., most recent start first.
+13 more trials See the organization page
Similar trials
Same condition (Idiopathic Pulmonary Fibrosis) and phase, most recent start first.
+132 more trials See the condition page